| Literature DB >> 35938169 |
Dajun Fang1, Yan Fang1, Weiqiang Zhang1, Yun Xiang1, Xi Cheng1, Mingfeng Liang1, Huimin Xia1.
Abstract
Background: Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific complication characterized by pruritus without skin damage and jaundice. The poor perinatal outcomes include fetal distress, preterm birth, and unexpected intrauterine death. However, the mechanism of ICP leading to poor prognosis is still unclear.Entities:
Keywords: competing endogenous RNA (ceRNA) network; intrahepatic cholestasis of pregnancy; quantitative proteomics; regulatory mechanism; target therapy
Year: 2022 PMID: 35938169 PMCID: PMC9354660 DOI: 10.3389/fcell.2022.854425
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Top 30 nodes ranked by the Degree method.
| Rank | Name | Score | Log2FC |
| Regulated |
|---|---|---|---|---|---|
| 1 | NEDD8 | 8 | −0.341 | 0.039 | Down |
| 2 | ATG5 | 6 | −0.347 | 0.022 | Down |
| 2 | FECH | 6 | 0.382 | 0.035 | Up |
| 4 | ACAT2 | 5 | 0.575 | 0.001 | Up |
| 4 | HBE1 | 5 | 0.952 | 0.019 | Up |
| 6 | ACOX3 | 4 | −0.287 | 0.049 | Down |
| 6 | CTPS2 | 4 | 0.332 | 0.032 | Up |
| 6 | GABARAPL2 | 4 | 0.465 | 0.004 | Up |
| 6 | GABARAPL1 | 4 | −0.278 | 0.028 | Down |
| 6 | MLST8 | 4 | −0.494 | 0.001 | Down |
| 6 | PLEK | 4 | 0.363 | 0.049 | Up |
| 6 | RANBP6 | 4 | 0.483 | 0.006 | Up |
| 6 | HMBS | 4 | 0.685 | 0.013 | Up |
| 6 | PRKAG2 | 4 | −0.362 | 0.042 | Down |
| 6 | SDC1 | 4 | −0.541 | 0.01 | Down |
| 16 | PBDC1 | 3 | −0.293 | 0.037 | Down |
| 16 | ECI2 | 3 | −0.448 | 0.001 | Down |
| 16 | ACE | 3 | −0.431 | 0.034 | Down |
| 16 | PEX14 | 3 | −0.467 | 0.027 | Down |
| 16 | GNG10 | 3 | 0.531 | 0.035 | Up |
| 16 | ADSS1 | 3 | 0.548 | 0.027 | Up |
| 16 | PSAT1 | 3 | 1.767 | 0.01 | Up |
| 16 | WIPI1 | 3 | −0.308 | 0.008 | Down |
| 16 | RICTOR | 3 | −0.289 | 0.026 | Down |
| 16 | UROD | 3 | 0.419 | 0.031 | Up |
| 16 | PAK1 | 3 | −0.272 | 0.037 | Down |
| 16 | CREBBP | 3 | −0.397 | 0.048 | Down |
| 16 | SMARCB1 | 3 | −0.623 | 0.021 | Down |
| 16 | HBG1 | 3 | 1.554 | 0.003 | Up |
| 16 | HBM | 3 | 1.111 | 0.011 | Up |
FIGURE 1Functional enrichment analysis of differentially expressed proteins based on quantitative proteomics. (A) Results of OPLS-DA analysis. (B) Heatmap of ICP differentially expressed proteins. (C) Volcano map of ICP differentially expressed proteins. (D) Histogram about the number of differentially expressed proteins. (E) GO analysis of ICP differentially expressed proteins. (F) KEGG pathway analysis of ICP differentially expressed proteins. (G) Domain enrichment analysis of ICP differentially expressed proteins. (H) KOG enrichment analysis of ICP differentially expressed proteins.
FIGURE 2Selection of core proteins from the PPI network. (A) PPI network of ICP differentially expressed proteins. (A) Results from the STRING database. (B) Results from the Cytoscape database. Red color: upregulated proteins; blue color: downregulated proteins. (B) Network about enriched terms of ICP differentially expressed proteins in the Metascape database (color by cluster ID). (C) MCODE analysis of ICP differentially expressed proteins and functional enrichment analysis of proteins in MCODE 1/2. (D) Summary of enrichment analysis in Cell Type Signature. (E) Summary of enrichment analysis in DisGeNET. (F) PPI network by value of protein expression difference.
FIGURE 3Expression of core proteins. (A) Expression of upregulated proteins. (B) Expression of downregulated proteins. Error bars, SD. *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 4Tissue specificity of the protein expression. (A) Summary of enrichment analysis in PaGenBase. (B) Expression positioning of SIGLEC6, HBG2, and GH2 in the BioGPS database.
Correlation between intrahepatic cholestasis of pregnancy and clinicopathologic parameters.
| Parameter | N (%) | Intrahepatic cholestasis of pregnancy | ||
|---|---|---|---|---|
| NC Group | ICP Group |
| ||
| Age (years) | 0.6563 | |||
| <30 | 10 (50) | 4 | 6 | |
| ≥30 | 10 (50) | 6 | 4 | |
| Delivery gestational age (week) |
| |||
| <39 + 2 | 10 (50) | 2 | 8 | |
| ≥39 + 2 | 10 (50) | 8 | 2 | |
| Fetal weight (g) | 0.1789 | |||
| <3100 | 10 (50) | 3 | 7 | |
| ≥3100 | 10 (50) | 7 | 3 | |
| PSAT1; HBM; PIP4K2B; YOD1; PKLR; SIGLEC6 | 0.1789 | |||
| High expression | 10 (50) | 3 | 7 | |
| Low expression | 10 (50) | 7 | 3 | |
| HBG1; SPI1; HBG2; HBE1 |
| |||
| High expression | 10 (50) | 2 | 8 | |
| Low expression | 10 (50) | 8 | 2 | |
| FOXK1 |
| |||
| High expression | 10 (50) | 1 | 9 | |
| Low expression | 10 (50) | 9 | 1 | |
| KRT72 |
| |||
| High expression | 10 (50) | 0 | 10 | |
| Low expression | 10 (50) | 10 | 0 | |
| HSPA13; EVA1A; EGFL7 | 0.1789 | |||
| High expression | 10 (50) | 7 | 3 | |
| Low expression | 10 (50) | 3 | 7 | |
| SLC13A3; MBD2; SP9; GPLD1; MYH7 |
| |||
| High expression | 10 (50) | 8 | 2 | |
| Low expression | 10 (50) | 2 | 8 | |
| TSFM; GH2; F7 | 0.6563 | |||
| High expression | 10 (50) | 6 | 4 | |
| Low expression | 10 (50) | 4 | 6 | |
| BLOC1S1 |
| |||
| High expression | 10 (50) | 9 | 1 | |
| Low expression | 10 (50) | 1 | 9 | |
The bold values are intended to highlight statistically significant p values.
FIGURE 5ceRNA and transcription factor regulatory network of 12 clinically significant proteins. (A) Transcription factor regulatory network of 12 clinically significant proteins. (B) Table of transcription factor regulatory network and 12 clinically significant proteins ranked by degree and betweenness. (C) Three independent miRNA target databases were used to predict the potential miRNAs for SPI1, FOXK1, SLC13A3, and MBD2. (D) lncRNA–miRNA network.
FIGURE 6Validation of in vitro and in vivo experimental models. (A) HE results of the placental explant. NC Group: normal placenta; ICP group: normal placenta was stimulated for 48 h with 100 uM cholid acid. (B) Western blotting results and gray histogram of the placental explant. NC group: normal placenta; ICP group: the normal placenta was stimulated for 48 h with 100 uM cholid acid. (C)Appearance of fetal and placenta in ICP and normal pregnancy rat models. (D) Proportion of mature fetuses in ICP and normal pregnancy rat models. SD. *p < 0.05; **p < 0.01; ***p < 0.001.